NZ Immuno-Oncology Research Review Issue 16

In this issue:
  -  ICIs in melanoma and pre-existing autoimmune disease
  -  Trastuzumab during pregnancy
  -  Early anti-PD-1 discontinuation in advanced melanoma
  -  Nivolumab and ipilimumab for advanced rare genitourinary malignancies
  -  Oral side effects of ICIs
  -  Antibiotic and ICI response
  -  Low-dose pembrolizumab for advanced NSCLC
  -  Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer
  -  Health-related QOL in metastatic CRC: first-line pembrolizumab vs. chemotherapy
  -  Pembrolizumab vs. chemotherapy for metastatic triple-negative breast cancer

Download PDF Subscribe